性别因素对磷丙泊酚二钠抑制胃镜置入反应效力的影响

张怡 ,  方洁 ,  赵姝 ,  袁景丽 ,  任学军

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 908 -912.

PDF (1049KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 908 -912. DOI: 10.12092/j.issn.1009-2501.2026.07.006

性别因素对磷丙泊酚二钠抑制胃镜置入反应效力的影响

作者信息 +

Effect of gender on the efficacy of fospropofol disodium in inhibiting the reaction of gastroscopy insertion

Author information +
文章历史 +
PDF (1073K)

摘要

目的: 评价性别因素对磷丙泊酚二钠抑制胃镜置入反应效力的影响。方法: 本研究为前瞻性试验。选择拟行无痛胃镜检查患者,年龄 18~64 岁,BMI 18~25 kg/m2,ASA 分级Ⅰ或Ⅱ级。所有患者随机分为 3 组:男性组(M 组)、女性组(F 组)、性别不限组(C 组)。静脉注射纳布啡 0.2 mg/kg,1 min 后注射磷丙泊酚二钠,待改良警觉镇静评分(the modified observer's assessment of alertness and sedation,MOAA/S)≤3 分后由同一名高年资主治医师行胃镜检查。按照改良 Dixon 序贯法进行试验,每组首例患者磷丙泊酚二钠剂量均设定为 10 mg/kg。若在进镜时患者出现影响检查操作的反应,判定为阳性反应,则下一例患者剂量增加 1 mg/kg,否则降低 1 mg/kg,出现 7 个阳性反应和阴性反应交叉点时终止该组试验。同时观察不良反应的发生。使用 Probit 回归分析法分别计算出每组患者磷丙泊酚二钠的半数有效剂量(ED50)、95% 有效剂量(ED95)及 95% 可信区间(CI)。结果: M 组磷丙泊酚二钠 ED50: 14.713 mg/kg(95% CI 14.044~ 14.988 mg/kg),ED95: 16.854 mg/kg(95% CI 14.229~ 17.339 mg/kg),F 组磷丙泊酚二钠 ED50: 12.938 mg/kg(95% CI 12.072~ 13.363 mg/kg), ED95: 15.289 mg/kg(95% CI 12.265~16.293 mg/kg)。与 M 组比较,F 组 ED50 降低(P<0.05)。C 组磷丙泊酚二钠 ED50: 13.915 mg/kg(95%CI 13.110~ 13.977 mg/kg),ED95: 15.545 mg/kg(95%CI 13.311~ 15.675 mg/kg)。有 15 例(16%)患者出现感觉异常,2 例(2%)患者出现呼吸抑制。结论: 性别因素影响磷丙泊酚二钠抑制胃镜置入反应的效力,女性的效力高于男性。

Abstract

AIM: To evaluate the effect of gender on the efficacy of fospropofol disodium in inhibiting the reaction of gastroscopy insertion. METHODS: This study was a prospective trial. Patients scheduled for painless gastroscopy, aged 18 to 64 years, with a BMI of 18 to 25 kg/m2, and ASA physical status classification Ⅰ or Ⅱ, were selected and divided into three groups randomly: male group (M group), female group (F group), and gender-unrestricted group (C group). A dose of 0.2 mg/kg of nalbuphine was intravenously injected, followed by fospropofol disodium 1 minutes later. When the modified observer's assessment of alertness and sedation (MOAA/S) ≤3, gastroscopy was performed by an experienced senior physician. According to the improved Dixon sequential method, the dose of fospropofol disodium for the first patient was set at 10 mg/kg. If the patient showed any reaction affected the procedure during the insertion of the endoscope, it was judged as a positive reaction, and the dose for the next patient was increased by 1 mg/kg; otherwise, it was decreased by 1 mg/kg. The trial was terminated when there were 7 positive and negative reaction crossover points, and adverse reactions were observed. The dose-response relationship was calculated by probit regression analysis method. RESULTS: The ED50 of fospropofol disodium in group M was 14.713 mg/kg (95% CI 14.044-14.988 mg/kg), ED95 was 16.854 mg/kg (95% CI 14.229-17.339 mg/kg). In group F, ED50 was 12.938 mg/kg (95% CI 12.072-13.363 mg /kg), and ED95 was 15.289 mg/kg (95% CI 12.265-16.293 mg /kg). Compared with group M, the ED50 of group F was decreased (P<0.05). The ED50 of fospropofol disodium in group C was 13.915 mg/kg (95%CI 13.110-13.977 mg/kg), and ED95 was 15.545 mg/kg (95%CI 13.311-15.675 mg/kg). Abnormal sensations occurred in 15 patients (16%), and respiratory depression occurred in 2 cases (2%). CONCLUSION: Gender factors influence the efficacy of sodium phosphopropofol in suppressing the response to endoscope insertion, with higher efficacy observed in females than that in males.

关键词

性别因素 / 胃镜检查 / 磷丙泊酚二钠 / 纳布啡 / 剂量效应关系

Key words

gender factors / gastroscopy / fospropofol disodium / nalbuphine / dose-response relationship

引用本文

引用格式 ▾
张怡,方洁,赵姝,袁景丽,任学军. 性别因素对磷丙泊酚二钠抑制胃镜置入反应效力的影响[J]. 中国临床药理学与治疗学, 2026, 31(7): 908-912 DOI:10.12092/j.issn.1009-2501.2026.07.006

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Early DS, Lightdale JR, Vargo JJ, et al. Guidelines for sedation and anesthesia in GI endoscopy[J].Gastrointest Endose, 2018, 87(2): 327-337.

[2]

陈蒙光, 刘继珍, 丁宁, 等. 复合阿芬太尼时环泊酚在不同性别患者中抑制气管插管反应的半数有效剂量[J].临床麻醉学杂志, 2023, 39(9): 944-947.

[3]

宜昌人福药业有限责任公司. 盐酸纳布啡注射液中文说明书[Z].2020.

[4]

磷丙泊酚二钠临床应用指导意见专家组. 磷丙泊酚二钠临床应用指导意见[J].中华麻醉学杂志, 2023, 43(8): 912-915.

[5]

Wu CM, Zhang WS, Liu J, et al. Efficacy and safety of fospropofol disodium for injection in general an, esthesia induction for adult patients: a phase 3 trial[J].Front Pharmacol, 2021, 12: 687894.

[6]

中华医学会麻醉学分会诊疗性操作的镇静与麻醉方案指导意见工作组. 诊疗性操作的镇静与麻醉方案指导意见 (二)[J].中华麻醉学杂志, 2023, 43(6): 648-657.

[7]

阿尔达克·夏买提, 魏靖茹, 陆天佑, 等. 胸腹按压对无痛胃镜患者丙泊酚镇静引起呼吸抑制的预防[J].中山大学学报: 医学科学版, 2022, 43(4): 631-638.

[8]

Albert SG, Sitaula S.Etomidate, adrenal insufficiency and mortality associated with severity of illness: a meta-analysis[J].J Intensive Care Med, 2021, 36(10): 1124-1129.

[9]

Liu LQ, Hong PX, Song XH, et al. Design, synthesis, and activity study of water-soluble, rapid-release propofol prodrugs[J].J Med Chem, 2020, 63(14): 7857-7866.

[10]

Filipeseu D, Stefan M. Sex and gender differences in anesthesia: relevant also for perioperative safety[J].Best Pract Res Clin Anaes-thesiol, 2021, 35(1): 141-153.

[11]

王晨旭, 周琰, 李依泽, 等. 性别因素对复合芬太尼时环泊酚用于胃镜检查术麻醉效力的影响[J].中华麻醉学杂志, 2023, 43(5): 585-587.

[12]

李平乐, 杨智虎, 邢飞, 等. 肥胖因素对复合阿芬太尼时瑞马唑仑用于无痛胃镜检查术量效关系的影响[J].中华麻醉学杂志, 2022, 42(6): 712-715.

[13]

董力, 周枫. 甲苯磺酸瑞马唑仑联合瑞芬太尼麻醉对老年脊柱外科手术患者血流动力学和血清炎症因子水平的影响[J].中国临床药理学与治疗学, 2023, 28(12): 1372-1377.

[14]

陆方舟, 刘美娟, 曾琼, 等. 环泊酚复合舒芬太尼在颅内动脉瘤栓塞术患者中抑制气管插管反应的半数有效剂量[J].中国临床药理学与治疗学, 2025, 30(8): 1092-1098.

[15]

金晶星, 梅凤美, 赵金兵, 等. 舒更葡糖钠复合格隆溴铵、新斯的明在术中神经电生理监测时逆转肌松作用的半数有效剂量[J].中国临床药理学与治疗学, 2025, 30(11): 1536-1540.

基金资助

河南省卫生健康委河南省中医药科研专项课题(2025ZY2010)

AI Summary AI Mindmap
PDF (1049KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉